文献速递垂体与肾上腺疾病

生长抑素受体配体治疗期间胰岛素样生长因子1正常化可预测肢端肥大症手术治愈

Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该回顾性观察研究纳入1990至2018年间接受生长抑素受体配体(SRL)治疗后行垂体手术的272例肢端肥大症患者,比较SRL治疗期间胰岛素样生长因子1(IGF-1)正常化者与未正常化者的手术结局。结果显示IGF-1正常化者手术治愈率显著高于未正常化者(83.9% vs 52.4%,P < .001),多因素分析证实IGF-1正常化是良好手术结局的独立预测因素。

要点

  • SRL治疗期间IGF-1正常化者手术治愈率83.9%,未正常化者52.4%(P < .001)。
  • 多因素分析显示IGF-1正常化、无海绵窦侵犯、肿瘤最大径小是独立预测因素。
  • IGF-1正常化在三种SRL类型间相似(P = .88)。

核心结论

  • SRL治疗期间IGF-1水平正常化是肢端肥大症患者良好手术结局的独立预测因素。

研究设计与样本

  • 回顾性观察研究,纳入1990至2018年间在某三级医疗中心接受SRL治疗并随后由熟练神经外科医生行垂体手术的272例肢端肥大症患者。

主要发现

  • SRL治疗期间IGF-1正常化见于62例患者(22.8%),三种SRL类型间相似(P = .88)。
  • 总体手术缓解率为59.6%。
  • IGF-1正常化者手术治愈概率高于未正常化者(83.9% vs 52.4%,P < .001)。
  • 多因素分析证实,无海绵窦侵犯、肿瘤最大径小及SRL治疗期间IGF-1正常化是仅有的与良好手术结局独立相关的因素。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Treatment with somatostatin receptor ligands (SRLs) is often given before pituitary surgery to patients with acromegaly. OBJECTIVE: To study whether the response to treatment with SRLs is predictive of surgical outcome. DESIGN: Retrospective, observational study. SETTING: Tertiary care center. PATIENTS: We investigated 272 patients with acromegaly who had been treated with an SRL between 1990 and 2018. INTERVENTION: All patients underwent pituitary surgery performed by a skilled neurosurgeon. MAIN OUTCOME MEASURE: Outcome of pituitary surgery in patients who had normalization of insulin-like growth factor 1 (IGF-1) levels during SRL therapy in comparison with patients who did not normalize IGF-1 levels. RESULTS: Normalization of IGF-1 levels during SRL treatment occurred in 62 patients (22.8%) and was similar for the 3 different types of SRL (P = .88). Surgical remission occurred in 59.6% of the patients. Patients who normalized IGF-1 levels during SRL treatment had a higher probability of surgical cure than patients without IGF-1 normalization (83.9% vs 52.4%, respectively; P < .001). Multivariate analysis confirmed that lack of cavernous sinus invasion, small maximum tumor diameter, and IGF-1 normalization during SRL therapy were the only factors independently associated with a favorable surgical outcome. CONCLUSIONS: Our study demonstrates that the normalization of IGF-1 levels during treatment with SRLs is an independent predictive factor of a favorable surgical outcome. The underlying mechanisms remain unclear, but an optimal response to medical therapy may be a characteristic of less aggressive tumors that are more likely to be entirely removed at surgery.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Losa M, Garbin E, Pedone E, et al. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly. J Clin Endocrinol Metab. 2020. PMID: 32609842. doi:10.1210/clinem/dgaa424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。